Monitoring, recovery and therapy continue beyond the hospital.
The category window is open
Clinical infrastructure for care beyond the hospital.
Care is moving home. Synra connects patients, devices, edge AI and clinical teams through one secure home endpoint, turning fragmented health signals into clinically usable trajectory intelligence.
Built before home-based care becomes the default.
The category window
Care is decentralizing. Clinical infrastructure has not caught up.
Hospitals increasingly move monitoring, recovery and chronic care into the home. Yet clinical teams still depend on fragmented apps, isolated devices and patient-led escalation. Synra is designed to become the controlled infrastructure layer between the home and the clinic.
Devices, symptoms, routines and biomarkers remain disconnected.
The care team often sees deterioration only after escalation.
One trusted endpoint creates context, continuity and earlier action.
132-133Mpeople in the initial entry region
3clinical entry paths
6starting clinical areas
The product
A controlled clinical endpoint, not another healthcare app.
Synra owns the point where home data becomes clinical context. That position combines hardware, local intelligence, secure transfer and workflow integration in one extensible platform.
Pair medical devices, wearables, patient input and partner diagnostics.
Run local models for signal quality, personal baselines and risk patterns.
Filter locally and transfer relevant context through encrypted connections.
Give clinical teams trajectories, explainable signals and escalation context.
Synra clinical layer
Connected
Home devices
Synra edge
Encrypted context
Care team
The investment logic
A clinical wedge with recurring economics and platform upside.
The base case does not depend on consumer wellness adoption. Synra starts where follow-up pressure is measurable, care pathways are identifiable and clinical value can be validated.
Clinical wedge
Post-acute follow-up, therapy control and chronic-pattern monitoring create focused entry paths.
Recurring economics
Device revenue is reinforced by subscriptions, indication modules, services and diagnostics partners.
Defensible position
The moat combines a controlled home touchpoint, longitudinal data, clinical workflow and privacy design.
Platform expansion
Validated third-party modules can add licensing, integration and ecosystem revenue over time.
Second horizon
14-24x
Longevity TAM versus the clinical core market.
Valuation upside
Clinical credibility first. Healthspan scale second.
Synra does not enter longevity as a wellness gadget. The platform earns trust through validated home monitoring, longitudinal data quality and clinical workflows. That foundation can later support premium self-pay programs, biomarker modules and partner-led healthspan services.
Phase 1
Clinical validation
USD 75-130B clinical core
Phase 2
Healthspan services
USD 1.8T TAM anchor
The investor window
The next value inflections are visible.
The current build phase precedes product validation, manufacturing readiness and regional clinical proof. Each milestone is designed to reduce a different category of execution risk.
Prototype design
Target architecture, hardware concept, security, interfaces and regulatory structure.
EUR 1.2 millionDeployable MVP
Product-near MVP for controlled clinical pilots and market-entry preparation.
EUR 1.2 millionRegional expansion
Clinical rollout, production scale, modules and expansion across the entry region.
EUR 25-50M seed planContinue diligence
Go deeper into the technology, market assumptions and execution path.
Investor Q&A
Interrogate the investment case.
Ask about the platform, market assumptions, business model, roadmap, privacy design or technical moat. The assistant answers from the Synra website and investor source documents.